Drug discovery and development – Page 33
-
NewsDoctors turn to experimental Ebola treatments
Drugs and vaccines untested in humans are being trialled on Ebola patients
-
Business
Single shot antibiotic approved for skin infections
Third drug in three months approved under US antimicrobials incentive scheme
-
NewsCall for new models to pay for antibiotics
UK government report on ways to fight resistance follows prime minister’s call for global action
-
NewsRenewed focus on dementia checked by drug challenges
‘Ticking time bomb’ of global neurodegenerative disease burden will be difficult to defuse
-
-
NewsChina gets tough with polluters
Amendments to country’s 25-year-old environment law paves the way for unlimited fines for environmental damage
-
CareersRemote possibilities
Now you can graduate in drug discovery without ever leaving the house, as Sarah Houlton finds out
-
ResearchDual warhead kills and disarms bacteria
Compound damages bacterial membrane and disables resistance mechanism in a two-pronged attack
-
-
OpinionEngineering serendipity
It takes more than random stumbling to find new reactions, says Derek Lowe
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
FeatureTargeting breast cancer
Tamoxifen has been treating breast cancer for 40 years, but few would have predicted how much this drug would contribute to saving lives, writes John Mann
-
OpinionKnown unknowns
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
-
-
-
ReviewIntroduction to biological and small molecule drug research and development
Big molecule pharma
-
NewsCroatia's vaccines manufacturer left hanging as it enters administration
Lack of government investment puts national immunology institute in crisis
-
OpinionIs there a drug for that?
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
-
OpinionPut the chemistry back in medicinal chemistry
Pursuing skewed priorities and easy options has impoverished the pharmaceutical industry, says David Lathbury.
-
OpinionRolling boulders uphill
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?